Neoadjuvant FOLFOX-bev, without radiation, for locally advanced rectal cancer.

摘要: 3511 Background: Preoperative 5FU-based chemo plus radiation therapy (RT) is standard for U.S. patients (pts) with locally advanced rectal cancer (RC). We conducted a pilot feasibility trial of pre-op FOLFOX-bevacizumab (bev) without RT good-risk RC. Methods: Pts clinical stage II-III RC (but not T4 tumors) who were candidates sphincter-sparing surgery, treated 6 cycles FOLFOX. Bev was included 1-4. then re-imaged and had repeat sigmoidoscopy endorectal ultrasound (ERUS) performed by their surgeon to assess the primary tumor response. Those stable/progressive disease be referred 5FU RT, followed those regression have surgery RT. Post-op planned any pts did an R0 resection. left investigator discretion, however FOLFOX recommended. The outcome resection rate. Secondary outcomes p...